Author

S. K. Chahal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1 Organism:mouse· 1

Frequent Co-Authors

A. J. Chalmers· 2 shared M. R. Jackson· 2 shared A. F. Rupp· 1 shared A. R. Richards· 1 shared A.-B. A. Oladipupo· 1 shared C. McSharry· 1 shared E. Curley· 1 shared E. Onwubiko· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. J. Chalmers

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ClonoScreen3D: a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma

M. R. Jackson, A. R. Richards, A.-B. A. Oladipupo, S. K. Chahal, S. Caragher, A. J. Chalmers, N. Gomez-Roman

ClonoScreen3D is a 3D clonogenic screening platform that identifies radiosensitizers for glioblastoma by testing drug-radiation interactions using patient-derived cell lines.

International Journal of Radiation Oncology*Biology*Physics · Sep 1, 2024Peer-reviewedCancer Biology

Low-dose lung radiotherapy for COVID-19 lung disease: a pre-clinical efficacy study in a bleomycin model of pneumonitis.

M. R. Jackson, K. Stevenson, S. K. Chahal, E. Curley, G. Finney, R. Gutierrez-Quintana, E. Onwubiko, A. F. Rupp, K. Strathdee, M. K. MacLeod, C. McSharry, A. J. Chalmers

This study evaluates low-dose lung radiotherapy (LDLR) in a bleomycin pneumonitis model, finding that 1.0 Gy LDLR improves recovery and reduces inflammation, particularly in moderate cases.

bioRxiv · Mar 3, 2021Immunology